

nádorů či jinak specifikovaného rozšíření indikačních kritérií. Od roku 2022 jsou metody HIVEC a RITE pro indikované pacienty v ČR

dostupné a hrazené z prostředků veřejného zdravotního pojištění a přibývají tak reálné klinické zkušenosti z pracovišť, kde se využívají.

Není tedy důvod této možnosti u vybraných pacientů nevyužít.

Podpořeno MZ ČR – RVO (FNBr, 65269705).

LITERATURA

- Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). In: EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. Arnhem, The Netherlands: EAU Guidelines Office; 2022:1-58.
- Brausi M, Oddens J, Sylvester R, Bono A, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. *Eur Urol.* 2014;65(1):69-76.
- Pang KH, Noon AP. Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. *Transl Androl Urol.* 2019; 8(1):101-107.
- Hornák J, Brisuda A, Babjuk M. Selhání intravezikální BCG imunoterapie v terapii svalovinu neinvadujících nádorů močového měchýře – současnost a budoucnost léčby. *Rozhl Chir.* 2022;101(3):108-113.
- Hendricksen K. Device-assisted intravesical therapy for non-muscle invasive bladder cancer. *Transl Androl Urol.* 2019;8(1):94-100.
- Brisuda A. Nové možnosti intravezikální instilační terapie u karcinomu močového měchýře. *Ces Urol.* 2018;22(4):251-256.
- Kuncová J. Intravezikální, radiofrekvencí indukovaná chemohypertermie v léčbě svalovinu neinvadujících nádorů močového měchýře. *Ces Urol.* 2022;26(3):174-185.
- Melgarejo-Segura MT, Morales-Martínez A, Yáñez-Castillo Y, et al. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. *Urol Oncol.* 2022, doi: 10.1016/j.urolonc.2022.09.016. Online ahead of print.
- Tan WP, Chang A, Brousell SC, et al. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. *Int J Hyperthermia.* 2020;37(1):854-860.
- Seznam zdravotních výkonů. Registrační list – 76532 [online]. Praha: ÚZIS ČR, © 2016 [cit. 31-1-2023]. Available from: <http://szv.mzcr.cz/Vykony/Detail/76532>.
- Plata A, Guerrero-Ramos F, García C, González-Díaz A, et al. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. *J Clin Med.* 2021;10(21):5105.
- Angulo JC, Álvarez-Ossorio JL, Domínguez JL, et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. *Eur Urol Oncol.* 2022, doi: 10.1016/j.euo.2022.10.008. Online ahead of print.
- Tan WS, Prendergast A, Ackerman C, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. *Eur Urol.* 2022. doi: 10.1016/j.eururo.2022.08.003. Online ahead of print.
- Guerrero-Ramos F, González-Padilla DA, et al. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. *World J Urol.* 2022;40(4):999-1004.
- Pijpers OM, Hendricksen K, Mostafid H, et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. *Urol Oncol.* 2022;40(2):62.
- Stemberger A, Tan WP, Bello AP, et al. A multicenter study of 2-year outcomes following hyperthermia therapy with Mitomycin C in treating BCG unresponsive non-muscle invasive bladder cancer: recirculant hyperthermic intravesical chemotherapy. *J Urol.* 2022;207(5):E932.
- van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. *Int J Hyperthermia.* 2016;32(4):351-362.
- Seznam zdravotních výkonů. Registrační list – 76534 [online]. Praha: ÚZIS ČR, © 2016 [cit. 31-1-2023]. Available from: <http://szv.mzcr.cz/Vykony/Detail/76534>.
- Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. *J Clin Oncol.* 2003; 21(23):4270-4276.
- Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). *BJU Int.* 2011; 107(6):912-918.
- Arends TJ, Nativ O, Maffezzini M, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. *Eur Urol.* 2016;69(6):1046-1052.
- Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. *Eur Urol.* 2019;75(1):63-71.
- Witjes JA. Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need? *Eur Urol.* 2019;75(1):72-73.
- Brummelhuis ISG, Wimpey Y, Witjes-van Os HGJM, et al. Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. *Cancers.* 2021;13(3):377.
- Babjuk M. Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer. *Eur Urol.* 2022;81(5):541.
- Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol.* 2011;60(1):81-93.

S NÁMI SE NEZTRATÍTE

Časopis je indexován v databázi EBSCO

Využíváme systém **CrossRef**. S články můžete snadno pracovat díky jednoznačnému identifikátoru **DOI**.

